Our study aimed to explore the predictive value of blood-based biomarkers including cfDNA plasma mutation detection and drug level monitoring in patients with EGFR-mutated NSCLC treated with a first or second line EGFR-TKI. Here, EGFR is linked to non-small cell lung carcinoma.